During a live event, Steven I. Robinson, MBBS, discussed desmoid tumor statistics and management for symptomatic progression.

Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.

Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.

Mabwell's 7MW4911 receives FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising ...

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

FDA endorses bexmarilimab for higher-risk myelodysplastic syndromes, paving the way for accelerated approval and promising ...

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

A groundbreaking study reveals ctDNA testing outperforms traditional imaging in predicting outcomes for large B-cell lymphoma ...

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high ...

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ...

During a live event, Tian Zhang, MD, MHS, discussed options and recent trial data for treating metastatic hormone-sensitive ...

A new study reveals personalized treatment strategies for HER2-negative breast cancer, optimizing antibody-drug conjugate sequencing based on tumor characteristics.